Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis

•We compared the effectiveness of different therapies in relapsed platinum-sensitive, BRCA-wild type, ovarian cancers using a network meta-analysis (NMA).•In total, 17 RCTs (n = 9405) comparing various strategies were included.•The risk of death was significantly decreased with carboplatin + pegylated liposomal doxorubicin + bevacizumab compared to platinum-based doublet CT.•Secondary cytoreduction followed by CT, and platinum-based CT with bevacizumab were better than CT alone for PFS.